Enfortumab vedotin (EV), targeting Nectin‐4, was granted accelerated approval by the FDA and EMA for mUC patients who had previously received both platinum‐based chemotherapy regimen and immunotherapy,92, 93 and Sacituzumab govitecan which recognizes Trop‐2‐expressing cancer cells has received accelerated FDA approval for mUC patients with prior platinum and immunotherapy pretreatment.84, 94. The gene discussed is TACSTD2; the disease is cancer.